Land: Australia
Språk: engelsk
Kilde: Department of Health (Therapeutic Goods Administration)
gadoteric acid, Quantity: 279.32 mg/mL
Guerbet Australia Pty Ltd
Gadoteric acid
Injection, solution
Excipient Ingredients: meglumine; water for injections
Intravenous
10 (only for plastic syringe), 1
Not scheduled. Not considered by committee
Dotarem is indicated, in adults and children, for use with magnetic resonance imaging to provide contrast enhancement for intracranial and spinal lesions with abnormal blood brain barrier or abnormal vascularity, and for whole body imaging (see clinical studies).
Visual Identification: Clear, colourless to yellow solution.; Container Type: Syringe; Container Material: PP; Container Life Time: 3 Years; Container Temperature: Store below 30 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert
Registered
2010-08-26
1(12) AUSTRALIAN PRODUCT INFORMATION DOTAREM ® (GADOTERIC ACID) SOLUTION FOR INJECTION 1 NAME OF THE MEDICINE Gadoteric acid. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION DOTAREM (gadoteric acid) paramagnetic contrast media for Magnetic Resonance Imaging (MRI). Each vial or pre-filled syringe contains the active ingredient gadoteric acid 279.32 mg/mL (equivalent to 0.5 mmol/mL). Gadoteric acid is a complex of the paramagnetic ion gadolinium oxide 90.62 mg/mL with DOTA (1,4,7,10–tetraazacyclododecane–N,N’,N’’,N’’’–tetraacetic acid) 202.46 mg/mL. Chemical characteristics of the formulation: Osmolality:1350 mOsm.kg-1, Viscosity at 20°C: 3.2 mPa.s, Viscosity at 37°C: 2.0 mPa.s, pH: 6.5 – 8.0. For the full list of excipients see Section 6.1 List of excipients. 3 PHARMACEUTICAL FORM Solution for injection. DOTAREM is a clear, colourless to yellow solution available in vials or pre-filled syringes intended for intravenous injection. 4 CLINICAL PARTICULARS 4.1 T HERAPEUTIC INDICATIONS DOTAREM is indicated, in adults and children, for use with magnetic resonance imaging to provide contrast enhancement for intracranial and spinal lesions with abnormal blood brain barrier or abnormal vascularity, and for whole body imaging (see Section 5.1 Pharmacodynamic properties - Clinical trials,). 4.2 D OSE AND METHOD OF ADMINISTRATION DOSAGE The lowest effective dose should be used. The dose should be calculated based on the patient’s body weight and should not exceed the recommended dose per kilogram of body weight detailed in this section. ADULTS (≥ 18 YEARS) The maximum recommended dose is 0.1 mmol/kg, i.e. 0.2 mL/kg for adults. 2(12) PAEDIATRICS (0 TO 18 YEARS) The maximum recommended dose is 0.1 mmol/kg, i.e. 0.2 mL/kg for children and infants. METHOD OF ADMINISTRATION DOTAREM is intended for intravenous administration only. Volumes required for doses of 0.1 mmol/kg are shown below. WEIGHT (KG) VOLUME (ML) REQUIRED FOR A DOSE OF 0.1 MMOL/KG 10 2 20 4 30 6 40 8 50 10 60 12 70 14 80 16 90 18 100 20 If DOTA read_full_document
1(12) AUSTRALIAN PRODUCT INFORMATION DOTAREM ® (GADOTERIC ACID) SOLUTION FOR INJECTION 1 NAME OF THE MEDICINE Gadoteric acid. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION DOTAREM (gadoteric acid) paramagnetic contrast media for Magnetic Resonance Imaging (MRI). Each vial or pre-filled syringe contains the active ingredient gadoteric acid 279.32 mg/mL (equivalent to 0.5 mmol/mL). Gadoteric acid is a complex of the paramagnetic ion gadolinium oxide 90.62 mg/mL with DOTA (1,4,7,10–tetraazacyclododecane–N,N’,N’’,N’’’–tetraacetic acid) 202.46 mg/mL. Chemical characteristics of the formulation: Osmolality:1350 mOsm.kg-1, Viscosity at 20°C: 3.2 mPa.s, Viscosity at 37°C: 2.0 mPa.s, pH: 6.5 – 8.0. For the full list of excipients see Section 6.1 List of excipients. 3 PHARMACEUTICAL FORM Solution for injection. DOTAREM is a clear, colourless to yellow solution available in vials or pre-filled syringes intended for intravenous injection. 4 CLINICAL PARTICULARS 4.1 T HERAPEUTIC INDICATIONS DOTAREM is indicated, in adults and children, for use with magnetic resonance imaging to provide contrast enhancement for intracranial and spinal lesions with abnormal blood brain barrier or abnormal vascularity, and for whole body imaging (see Section 5.1 Pharmacodynamic properties - Clinical trials,). 4.2 D OSE AND METHOD OF ADMINISTRATION DOSAGE The lowest effective dose should be used. The dose should be calculated based on the patient’s body weight and should not exceed the recommended dose per kilogram of body weight detailed in this section. ADULTS (≥ 18 YEARS) The maximum recommended dose is 0.1 mmol/kg, i.e. 0.2 mL/kg for adults. 2(12) PAEDIATRICS (0 TO 18 YEARS) The maximum recommended dose is 0.1 mmol/kg, i.e. 0.2 mL/kg for children and infants. METHOD OF ADMINISTRATION DOTAREM is intended for intravenous administration only. Volumes required for doses of 0.1 mmol/kg are shown below. WEIGHT (KG) VOLUME (ML) REQUIRED FOR A DOSE OF 0.1 MMOL/KG 10 2 20 4 30 6 40 8 50 10 60 12 70 14 80 16 90 18 100 20 If DOTA read_full_document